As shown in Figure 4, the odds of vortioxetine treated patients achieving a ≥50% MADRS score reduction from baseline was about 3 times higher than placebo treated patients (Overall OR = 2.87; 95 ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine can effectively treat depression, but whether depressed patients with alcohol use disorder can safely use ketamine ...

The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder ... limits accessibility. Esketamine, a key component ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.